6533b82dfe1ef96bd1291fc4
RESEARCH PRODUCT
Clinical impact of the immunome in lymphoid malignancies: the role of Myeloid-Derived Suppressor Cells
F. CoppolinoCalogero VetroFlavia AncoraNunziatina Laura ParrinelloFabrizio PuglisiDaniele TibulloCesarina GiallongoSalvatore Antonino RaccuiaSalvatore Antonino RaccuiaPiera La CavaMaria Violetta BrundoAlessandra Romanosubject
Cancer ResearchPrognostic factorLymphomaMDSCMDSCsContext (language use)ReviewBioinformaticslcsh:RC254-282law.inventionImmune systemlawmedicinebusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHematologic Diseasesmicroenvironment3. Good healthLymphomaImmunomeOncologyMyeloid-derived Suppressor CellCancer researchSuppressorbusinessprognosticationdescription
The better definition of the mutual sustainment between neoplastic cells and immune system has been translated from the bench to the bedside acquiring value as prognostic factor. Additionally, it represents a promising tool for improving therapeutic strategies. In this context, myeloid-derived suppressor cells have gained a central role in tumor developing with consequent therapeutic implications. In this review, we will focus on the biological and clinical impact of the study of myeloid-derived suppressor cells in the settings of lymphoid malignancies.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-05-21 | Frontiers in Oncology |